New cytochrome P450 2D656 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes

Drug Metabolism and Disposition

Volumn 34, Issue 8, 2006, Pages 1411-1416

  Li, Li ^a   Pan, Run Mei ^a   Porter, Todd D ^a   Jensen, Neil S ^b   Silber, Paul ^b   Russo, Guy ^c   Tine, John A ^c   Heim, John ^d   Ring, Barbara ^d   Wedlund, Peter J ^a  

^a University of Kentucky   (United States)

^b In Vitro Technologies Inc   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; MIDAZOLAM;

ALLELE; ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVITY; EXON; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER MICROSOME; METABOLITE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOP CODON;

ALLELES; BASE SEQUENCE; CRYOPRESERVATION; CYTOCHROME P-450 CYP2D6; ETHANOLAMINES; GENOTYPE; HEPATOCYTES; HUMANS; MICROSOMES, LIVER; MIDAZOLAM; MOLECULAR SEQUENCE DATA; PHENOTYPE;

EID: 33746041490     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.009548     Document Type: Article

References (35)

1. Ariyoshi N, Sawamura Y-I, and Kamataki T (2001) A novel single nucleotide polymorphism altering stability and activity of CYP2A6. Biochem Biophys Res Commun 281:810-814.
2. Cai WM, Nikoloff DM, Pan RM, deLeon J, Fanti P, Fairchild M, Koch WH, and Wedlund PJ (2006). CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing. Pharmacogenomics J, in press.
3. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ, and Broly F (2001) Five novel natural allelic variants - 951 A>C, 1042G>A (D348N), 1156A>T (1386F), 1217G>A (C406Y) and 1291C>T (C431Y) - of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 17:355-356.
4. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, deLeon J, Koch WH, and Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542-551.
5. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
6. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, and Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387.
7. Ferguson RJ, de Morais SMF, Benhamous S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, et al. (1998) A new genetic defect in human CYP2C10: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
8. Fernandes-Salguero P, Hoffman SMG, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR, et al. (1995) Genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. Am J Hum Genet 57:651-660.
9. Gaedigk A, Bhathena A, Ndjountche L, Pearce RE, Abdel-Rahman SM, Alander SW, Bradford LD, and Leeder JS (2005) Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 5:173-182.
10. Gaedigk A, Ndjountche L, Gaedigk R, Leeder JS, and Bradford LD (2003) Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42 in African-American subjects. Clin Pharmacol Ther 73:575-576.
11. Goods S and Tyndale RF (2002) Genotyping human CYP2A6 variants. Methods Enzymol 357:59-69.
12. Haberl M, Anwald B, Klein K, Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA, and Wojnowski L (2005) Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Pharmacogenomics 15:609-624.
13. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
14. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, and Goldstein JA (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290:635-640.
15. Ingelman-Sundberg M, Daly AK, and Nebert DW (2005). Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.imm.ki.se/ CYPalleles/. 2005.
16. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, and Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity ot phenytoin. Pharmacogenetics 11:803-808.
17. Kiyotani K, Fujieda M, Yamazaki H, Shimada T, Guengerich FP, Parkinson A, Nakagawa K, Ishizaki T, and Kamataki T (2002). Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab Pharmacokinet 17:482-487.
18. Komura H and Iwaki M (2005) Usefulness of hepatocytes for evaluating the genetic polymorphism of CYP2D6 substrates. Xenobiotica 35:575-587.
19. Larrey D, Funck-Brentano C, Breil P, Vitaux J, Theodore C, Babany G, and Pessayre D (1983) Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 32:1063-1068.
20. Loffler BM and Kunze H (1989) Refinement of the Coomassie brilliant blue G assay for quantitative protein determination. Anal Biochem 177:100-102.
21. Lovlie R, Daly AK, Molven A, Idle JR, and Steen VM (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 392:30-34.
22. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ, Meyer UV, and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
23. McConnachie L, Bodor M, Kowdley K, Levy A, Tung B, Thummel K, Phillips B, Bajpai M, Chi V, Esmay JD, et al. (2004) Human liver cytochrome P450 2D6 genotype, full-length messenger ribonucleic acid and activity assessed with a novel cytochrome P450 2D6 substrate. Clin Pharmacol Ther 75:282-297.
24. Oscarson M, Hidestrand M, Johansson I, and Ingelman-Sundberg M (1997) A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 52:1034-1040.
25. Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz MLB, Sinues B, Rautio A, and Ingelman-Sundberg M (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20:257-283.
26. Paschke T, Riefler M, Schuler-Metz A, Wolz L, Scherer G, McBride CM, and Bepler G (2001) Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method. Toxicology 168:259-268.
27. Pham C, Lu C, Fackett A, and Li AP (2000). Effects of cryopreservation on P450 oxidation and Phase II conjugation activities in human hepatocytes: results from hepatocytes from 30 donors. http://www.invitrotech.com/filelib/ CryoVsFreshPoster.pdf.
28. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, and Ingelman-Sundberg M (2001) Identification of a single nucleotide polymorphism in the TATA Box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460.
29. Ramamoorthy Y, Tyndale RF, and Sellers EM (2001) Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 11:477-487.
30. Rao Y, Hoffman E, Zia M, Bodin L, Zeman M, Sellers EM, and Tyndale RF (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping and in vivo effects on smoking. Mol Pharmacol 58:747-756.
31. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, and Dawson EP (2004) Genetic variations in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931.
32. Soyama A, Saito Y, Hanioka N, Maekawa K, Komamura K, Kamakura S, Kitakaze M, Tomoike H, Ueno K, Goto Y, et al. (2005). Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 20:24-33.
33. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, and Rettie AE (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361-367.
34. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang Z-Y, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, and Goldstein JA (1996) The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
35. Watkins PB, Wrighton SA, Maurel P, Scheutz EG, Mendez-Picon G, Parker GA, and Guzelian PS (1985) Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 82:6310-6314.